tumor and/or ascitic fluid of 16 patients were characterized for MSCs phenotype (CD73, CD90, CD105), CSCs markers (CD24, CD44, CD133), and hematopoietic stem and progenitor marker (CD34) and leukocyte common antigen (CD45). This evidence concerns the gene CD44 and neoplasm.